anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The critical sociological literature has explored social prescriptions on women's reproductive lives, trajectories, outcomes and aftermaths. However, little attention has been given to how these prescriptions are expressed through temporal negotiations. This article delves into the narratives of Jewish-Israeli women who have experienced stillbirths. In their narratives, these women contest expectations directed towards them in interactions with professionals, family and friends. Within these expectations, a form of dictation over their future comes into being, where a new pregnancy should quickly precede the stillbirth. The focus here lies on how these women navigate and contest these temporal expectations, carving out space for stillbirth as a meaningful and painful event that should be granted attention and for alternative forms of remembering their stillborn and caring for them after their death. They reshape their narratives through what I call "thickening a present tense" and extend care to the stillborn in the aftermath of the stillbirth. This work contributes to scholarly inquiries into reproductive life and probing time as a socially prescribed mechanism for the value and social distribution of care.
Since there is no significant difference in onset of effect after intravenous or intramuscular injection, usually there is no need to use the intravenous route. The drug is quickly effective after either route, with improvement sometimes noticeable a few minutes after injection. In emergency situations, when the condition of the patient is alarming, 1 to 2 mL of the injection normally will provide quick relief. If the parkinsonian effect begins to return, the dose can be repeated. 

Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.
BACKGROUND: Sarcopenia is characterized by low muscle strength, decreased muscle mass, and decline in physical performance. While the measurements of muscle strength and physical performance are easy to perform, an accurate evaluation of muscle mass is technically more demanding. We therefore evaluated the suitability of calf circumference (CC) as a clinical indicator for muscle mass.
METHODS: In a cross-sectional single-centre study, geriatric inpatients were assessed for sarcopenia according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) consensus. Calf circumference was tested for correlation with appendicular skeletal muscle mass index (ASMI). Receiver operating characteristic curves (ROC) were used to calculate the discriminatory value of the CC cut-off values to differentiate patients above and below ASMI cut-offs for sarcopenia.
RESULTS: In this study population (n = 305, age 83.5 ± 7.0 years, BMI 25.7 kg/m2, 65.6% female), the prevalence of sarcopenia was 22.6%. In subjects with low ASMI, mean CC was 29.5 ± 3.4 cm for females and 32.0 ± 3.4 cm for males. A positive relationship between CC and ASMI was found. The optimized cut-off value for CC to identify patients with low ASMI was <31.5 cm for females (sensitivity 78%, specificity 79%), and <33.5 cm for males (sensitivity 71%, specificity 62%).
CONCLUSION: In clinical settings where imaging technology for muscle mass quantification is not available, simple calf circumference measurement may be used as a dependable indicator for low muscle mass in older adults.
PURPOSE:To provide the titled bathing agent composed of mineral-containing wax as a main component, exhibiting body-warming effect comparable to the whole body bath by the heat-insulation effect of the wax film and the warming- promoting effect of the mineral components, and useful for the remedy of obesity and the promotion of health. CONSTITUTION:The objective hot-melt bathing agent for partial bathing of hand and foot, etc. is composed mainly of wax containing minerals (e.g. germanium, iron, etc.). The wax is paraffin wax, beeswax, Japan wax, etc. When the hand is immersed in the upper bath 2 and the foot in the lower bath 3, a wax film is formed on the surface of the hand and foot to effect the warming of the whole body. Furthermore, the mineral components in the bathing agent are ionized and taken in the body to promote the warming effect, accelerate the stimulation of the fat call, the melting, and the perspiration, and to remove excessive fat layer. A drug action can be attained by the addition of vitamins. The remedy of obesity, etc. can be carried out without causing the constriction of the heart as is in the case of the whole body bath.
A system, method and computer program product for determining cycling power. A plurality of force sensor readings are acquired from force sensors positioned underfoot. At least one revolution is identified. Force values are determined for the at least one revolution using aggregate force data. The cycling cadence, foot velocity, and foot angle are determined for each revolution. User mass is also determined. The cycling power associated with the force sensor readings is determined by inputting the force values, the cycling cadence, the foot velocity, and the foot angle, and the user mass to a machine learning model trained to predict the cycling power. The cycling power can then be provided to the user as feedback or stored for purposes such as later review and analysis. The inputs to the machine learning model can be determined entirely based off of sensor data received from a wearable device worn by the user.
The invention relates to a nutritional supplement comprising: a) between 9 and 17 wt. % of Spirulina maxima alga; b) between 20 and 40 wt. % of concentrated whey protein; c) between 10 and 40 wt. % of protein isolated from soya; y d) between 20 and 40 wt. % of coconut in powder form. The pharmaceutical form of said nutritional supplement is a powder for reconstituting a solution, a suspension, an emulsion, capsules, tablets, flakes or fruit-enriched bars, and can be used to improve the nutritional state of people who suffer from a rheumatic disease.
Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisolone is a white crystalline powder, very slightly soluble in water. It is designated chemically as pregna-1,4-diene-3,20-dione,11,17,21-trihydroxy-, (11ß)-. The structural formula is represented below:

C 21H 28O 5 M.W. 360.45 

Each tablet contains 5 mg of Prednisolone, USP for oral administration. Inactive ingredients include: anhydrous lactose, corn starch, sodium starch glycolate, and calcium stearate.
BACKGROUND: Necrotizing enterocolitis is the most severe life-threatening acquired gastrointestinal disorder among preterm neonates. We describe here an outbreak of Clostridium butyricum-related necrotizing enterocolitis in preterm neonates that occurred in three different neonatal centres, in southeast France.
METHODS: We defined a confirmed case of C. butyricum-related necrotizing enterocolitis in preterm neonates by the presence of clinical signs according to modified Bell criteria and C. butyricum identified from stool samples using real-time polymerase chain reaction or culture. A phylogenetic analysis of the isolated strains by whole-genome sequencing was also performed.
RESULTS: Between 5th and 27th January 2022, we identified 10 confirmed cases of C. butyricum-related necrotizing enterocolitis, including five from Neonatal Centre 1, four from Neonatal Centre 2, and one from Neonatal Centre 3. The attack rate of necrotizing enterocolitis in Neonatal Centre 1 was 7.1% (5/70). The positivity rate of C. butyricum detected from stool samples was higher during the outbreak period (37/276; 13.4%) than outside this period (7/369; 1.9%), while systematic screening was maintained (P<0.001). Phylogenetic analysis showed a clonality between strains inside four clusters. Two clusters included neonates hospitalized in different neonatal centres, suggesting the transmission of C. butyricum strains during the transfer of neonates between neonatal centres.
CONCLUSIONS: This outbreak of C. butyricum-related necrotizing enterocolitis confirms a cross-transmission between preterm neonates, including twin or triplet siblings, and involving necrotizing enterocolitis cases together with asymptomatic carriers. After three months of follow-up, no further cases were identified following the implementation of contact precautions with sporicidal agents.
INTRODUCTION: Reading disorders caused by homonymous visual field defects (HVFDs) have a significant impact on a patient's quality of life. However, no review has been conducted to evaluate the available evidence on the effects of rehabilitative interventions on reading disorders caused by HVFDs. Thus, the aim of this study was to systematically evaluate the effects of rehabilitative interventions on reading disorders caused by HVFDs.
METHODS: We searched the MEDLINE/PubMed, Cochrane Library, ClinicalTrials.gov, CINAHL, and ScienceDirect databases for relevant articles. Relevant search terms were used to identify reports of randomized controlled trials or randomized crossover trials published between January 1990 and December 2021. Only studies that included reading-speed-related outcomes were analyzed. Risk of bias was assessed using the PEDro scale. Meta-analysis was conducted using a random-effects model, and standardized mean differences (SMD) and 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using the Ι2 statistic.
RESULTS: Nine studies were included in the meta-analysis. The results showed that rehabilitative interventions significantly improved reading disorders caused by HVFDs (SMD = 0.30; 95% CI 0.08-0.51; P < 0.01; Ι2 = 0.0%). Subgroup analysis showed that reading training significantly improved reading disorders (SMD = 0.35; 95% CI 0.05-0.66; P = 0.02; Ι2 = 0.0%).
CONCLUSION: Reading disorders caused by HVFDs can be improved through rehabilitation. In addition, reading training for the improvement of eye movement and fixation to compensate for foveal and parafoveal visual field defects may improve reading speed.
Coronary MDCTA (multi-detector CT angiography) is a novel but already established and widespread diagnostic method to diagnose coronary artery disease. When performed with a 64-detector (slice) CT, its strength is an excellent negative predictive value, NPV (98%). Specificity (86%) is good but the positive predictive value (PPV) is only moderate (70%). This is due to the ability of MDCTA to detect even minor vessel wall changes before they are functionally significant, and the tendency of CT to overestimate the volume of dense calcifications. However, when coupled with a functional or flow-sensitive diagnostic test, such as PET perfusion or coronary doppler ultrasonography, one can assume that even the PPV may be as high as 95 %. Despite this assumption, there's no scientific evidence to support use of such hybrid multi-modality tests at present.

Our hypothesis is that improving the diagnostic accuracy of non-invasive diagnosis of coronary artery disease will decrease the proportion of patients that need catheter angiographies. The avoidance of these unnecessary invasive procedures will improve patients´ quality of life and may even redirect health care resources in a more efficient way.
At Northwestern Memorial Hospital in Chicago, IL USA, IVC filters are successfully removed \>95%. Technical failures, although rare, are usually related to excessive endoluminal scarring at the point of IVC filter implantation. Adjunctive (or advanced) removal techniques are often employed in difficult cases. The excimer laser sheath has been successfully used at Northwestern for patients who had failed all other retrieval techniques.

Before a patient is to undergo an IVC filter removal using the Excimer Laser Sheath they will be consented to participate in the chart review study and become a part of a registry kept at Northwestern Memorial Hospital. The procedure itself is not being used as part of the study. Chart reviews will be completed and data collected on the procedure to remove the filter. Follow up after the procedure by phone call and chart review will be completed at least once, 1 week after the filter removal.
The invention relates to the preparation method of a Diclazuril microemulsion. The preparation method is: (1) Diclazuril is put in tween-80 and stirred evenly; (2) Dimethylformamide is added in and stirred evenly; (3) glycerin and dimethoxymethane is added in and stirred evenly; (4) ethanolamine or triethanolamine is added in and stirred evenly; (5) water is added in and stirred evenly, and then the Diclazuril microemulsion is prepared. The invention adopts advanced microemulsion technology and slightly water soluble Diclazuril is prepared into Siclazuril microemulsion solution which is soluble with water in any ratio. The method greatly enhances the bioavailability of the product, prolongs the residence time of medicine in human body, and reduces the volume of use of drug. Compared with traditional solutions, the product greatly reduces the volume of use of organic solution and has reliable safety, few side effects, low toxicity, high treating effects, so is applicable to treat diseases caused by coccidian. Besides, the microemulsion can be directly taken after being mixed with water and the use is very convenient.
Procedure for the obtaining of a pharmaceutical preparation based on cardiac glycosid. It is part of a great number of nucleos consisting of a pharmaceutically indifferent material, on which a first layer of cardiac glycosid applies, so that in each particle there is a fractional amount of the therapeutically effective dosage. Subsequently it is covered with a second layer comprising an anionic carboxylic dificily soluble, or insoluble, in ph values of less than 7.5, weight soluble for a ph of higher value. Both layers apply from the respective solutions of their components, well by conventional coating or by spraying. The preparations obtained are used for controlled assimilation, in the acid environment of the stomach, of the cardiac glycosid. (Machine-translation by Google Translate, not legally binding)
Oral seliciclib at 1200mg b.i.d. for 3 consecutive days as an outpatient beginning on day 1 every 2 weeks for 3 cycles as run-in. Patients (randomized) continue on treatment if derived clinical benefit during run-in period.
OBJECTIVE: The initial therapeutic approach for diffuse large B-cell lymphoma (DLBCL) entails a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen. However, 40% of patients exhibit suboptimal responses, with some experiencing relapse and refractory conditions. This study aimed to explore novel therapeutic strategies and elucidate their underlying mechanisms in DLBCL.
METHODS: Bioinformatics techniques were employed to scrutinize correlations between the HDAC1, HDAC2, HDAC3, HDAC10, BTK, MYC, TP53, and BCL2 genes in DLBCL. In vitro experiments were conducted using DB and SU-DHL-4 cells treated with chidamide, orelabrutinib, and a combination of both. Cell viability was assessed by cell counting kit-8. Cell apoptosis and the cell cycle were determined using flow cytometry. Reactive oxygen species (ROS) production and mitochondrial function were assessed through ROS and JC-1 staining. RNA sequencing and western blot analyses were conducted to elucidate the molecular mechanisms underlying the combined action of chidamide and orelabrutinib in DLBCL cells.
RESULTS: This investigation revealed markedly enhanced antiproliferative effects when chidamide was combined with orelabrutinib. Compusyn software analysis indicated a synergistic effect of chidamide and orelabrutinib in inhibiting DLBCL cell proliferation, with a combination index (CI) < 1. This synergy further manifested as augmented cell cycle arrest, apoptosis induction, the downregulation of cell cycle-associated and antiapoptotic proteins, and the upregulation of proapoptotic proteins. Furthermore, the western blot and RNA-Seq findings suggested that combining chidamide and orelabrutinib modulated the PI3K/AKT/mTOR signaling pathway, thereby promoting DLBCL cell cycle arrest and apoptosis.
CONCLUSION: The findings of this study provide a compelling justification for the clinical utilization of chidamide and orelabrutinib to treat relapsed/refractory DLBCL.
The present invention discloses a Changshuning capsule and a preparation method thereof. The Changshuning capsule is prepared from Chinese Dwarf Cherry Seed, hemp fruit and alose powder according to the proportion of 1:1 to 10:0.1 to 0.2. The preparation method of the Changshuning capsule comprises the following steps: the Chinese Dwarf Cherry Seed and the hemp fruit are weighed according to the proportion of 1:1 to 10 and then are cleaned; 5 to 10 times amount of water is added to decoct the Chinese Dwarf Cherry Seed and the hemp fruit for 1 to 2 hr; the decocted liquid is filtered; then the filter liquid is taken; the steps are repeated in such a manner for twice to 3 times; the filter liquor is combined; then the combined filter liquor is moved to a baking box after being condensed to thick extractum; the extractum is baked to the dry extractum at the temperature of 50 to 70 DEG C; 0.1 to 0.2 portion of alose powder is added to be uniformly mixed; the mixture is continuously moved to the baking box to be baked at the temperature of 50 to 70 DEG C until the moisture content is below 3 to 5%; the final mixture is taken out to be ground into 60 to 80 meshes and then is encapsulated. The Changshuning capsule has the advantages of safety, small admit dose and efficiency. The toxicologic study indicates that the Changshuning capsule is safe and nontoxic. The research of the disease prevention and control center (the food health care function test unit designated by the State Ministry of Health) in Jiangsu province indicates that the Changshuning capsule has the action for loosening bowel to relieve constipation. Moreover, the Changshuning capsule obtains the health-care food approval documents of the State Ministry of Health.
This meta-analysis seeks to investigate the effects of renin-angiotensin-aldosterone system (RAAS) inhibitors on the recurrence of chronic subdural hematoma (cSDH). Following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, this study conducted a comprehensive online search across various databases, including PubMed, EMBASE, CINAHL, Web of Science, and Cochrane, without time restrictions. Two reviewers independently screened titles, abstracts, and full texts based on predetermined criteria, resolving any discrepancies through discussion or consultation with a third reviewer. The quality and risk of bias of the included studies were assessed using the Methodological Index for Non-Randomized Studies (MINORS) and Cochrane's tool for evaluating risk of bias in randomized controlled trials. Six studies aligned with the study objectives were included after a systematic search across 6 databases. The RAAS inhibitors group comprised 404 participants, while the control or placebo group included 1828 participants. Analysis for publication bias using the Egger test indicated no bias in the studies (P = 0.151). The odds ratio for cSDH recurrence with RAAS inhibitor use compared to non-use was reported as OR = 1.06; confidence interval 0.6-1.893, p-value = 0.818, showing no significant association between RAAS inhibitor use and cSDH recurrence. The results suggest no significant link between RAAS inhibitor use and cSDH recurrence. However, due to the limited number and design of studies, as well as the lack of clinical trials, further research is needed to determine the effectiveness of this treatment.
Hot saline with a temperature of 50°C used for irrigation during endoscopic sinus surgery. Frequency of the drug is according to the operative field and surgeon's need.
This invention relates to the use of a therapeutically effective amount of a non-immunosuppressive compound when preparing a medicament for treating neurological disorders in an animal, wherein said compounds has affinity for FKBP-type immunophilins. The FKBP-type immunophilin is FKBP-12. The immunophilin exhibits rotamase activity and the non-immunosuppressive compound inhibits the rotamase activity of the immunophilin. The neurological disorder is selected from the group consisting of peripheral neuropathies, and neurological pathologies related to neurodegeneration in an animal. The neurological disorder can also be Alzheimer's disease, Parkinson's disease or amyotrophic lateral sclerosis. Disclosed is also the use of a therapeutically effective amount of a non-immunosuppressive compound when preparing a medicament for stimulating growth of damaged nerves in mammals, wherein said compound has affinity for  FKBP-type immunophilins. The FKBP-type immunophilin is FKBP-12. The immunophilin exhibits rotamase activity and the non-immunosuppressive compound inhibits the rotamase activity of the immunophilin. Further disclosed is the use of a therapeutically effective amount of a non-immunosuppressive compound when preparing a medicament for prophylaxis neurodegeneration in an animal wherein said compound has affinity for  FKBP-type immunophilins and the FKBP-type immunophilin is FKBP-12. The immunophilin exhibits rotamase activity and the non-immunosuppressive compound inhibits the rotamase activity of the immunophilin. Also disclosed is the use of a therapeutically effective amount of a non-immunosuppressive compound to stimulate growth of damaged peripheral nerves.
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.
Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
An isolated nucleotide sequence encoding a urea transporter polypeptide or unique fragments of urea transporter polypeptide, is provided. One embodiment is an isolated DNA sequence (SEQ ID NO.:1) encoding a urea transporter polypeptide, that has at least two extended hydrophobic domains, each domain lacking interspersed hydrophilic domains. Also described are recombinant cells and plasmids containing the foregoing isolated DNA, preferably linked to a promoter. Isolated urea transporter polypeptide is provided, having at least two extended hydrophobic domains, each domain lacking interspersed hydrophilic domains (SEQ ID NO.:2). Portions of the foregoing isolated urea transporter polypeptides are also described. Antibodies with selective binding specificity for the polypeptides of the invention also are provided. 
     Methods for producing urea transporter polypeptide as well as methods for testing for modulators of urea transporter polypeptide activity are also described.